66
Participants
Start Date
June 26, 2023
Primary Completion Date
August 12, 2026
Study Completion Date
August 12, 2026
Autologous genetically modified ADP-A2M4CD8 cells
Infusion of autologous genetically modified ADP-A2M4CD8 cells on Day 1
Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab
Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1 followed by nivolumab 480 mg IV at Week 4 and then every four weeks
Clinica Universidad de Navarra, Madrid
Hospital Universitario Ramón y Cajal, Madrid
Hospital Universitario Fundación Jiménez Díaz, Madrid
Hospital Universitario 12 de Octubre, Madrid
Centro Oncologico Clara Campal, Madrid
Augusta University, Augusta
Cleveland Clinic Foundation, Cleveland
Hospotal Clinico Universitario de Valencia, Valencia
Karmanos Cancer Institute, Detroit
Avera Cancer Institute, Sioux Falls
Institut de Cancerologie de Strasbourg, Strasbourg
Centre Leon-Berard, Lyon
Institut de Cancerologie des Hospices Civils de Lyon, Pierre-Bénite
University of Oklahoma Health Sciences Center, Oklahoma City
Honor Health, Scottsdale
City of Hope, Duarte
Institut Gustave Roussy, Villejuif
Swedish Cancer Institute, Seattle
Rutgers Cancer Institute of NJ, New Brunswick
University Health Network (Princess Margaret Cancer Center), Toronto
Vall d'Hebron Unversity Hospital, Barcelona
University College of London Hospital, London
The Christie Hospital, Manchester
Lead Sponsor
GOG Foundation
NETWORK
Adaptimmune
INDUSTRY